843647-60-9

Basic information

• Product Name: (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide
• Synonyms: (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide
• CAS NO: 843647-60-9
• Molecular Weight: 356.353
• Mol File: 843647-60-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide(843647-60-9)
• EPA Substance Registry System: (S)-N-[3-(2-fluoro-4'-formylbiphenyl-4-yl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide(843647-60-9)

Safety Data

• Hazardous Substances Data: 843647-60-9(Hazardous Substances Data)

Upstream product

• 856677-03-7 (S)-5-(aminomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one 
• 656-65-5 3-fluoro-4-bromophenylamine 
• 1032827-78-3 (S)-2-((3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione 
• 1032827-77-2 2-((R)-3-(4-bromo-3-fluorophenylamino)-2-hydroxypropyl)isoindolin-1,3-dione 
• 87199-17-5 4-formylphenylboronic acid, 
• 149524-45-8 (S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidine-5-ylmethyl]acetamide 
• 72755-13-6 (3-fluoro-phenyl)-carbamic acid methyl ester 
• 372-19-0 meta-fluoroaniline 
• 856677-05-9 (5S)-N-[[3-(3-fluoro-4-bromophenyl)-2-oxo-oxazolidin-5-yl]methyl]acetamide 

Downstream Products

• 1032827-79-4 (S,E)-N-((3-(4-(4-(2-nitrovinyl)phenyl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1032827-80-7 (S,E)-methyl 3-(4-(2-fluoro-4-(5-(acetamidomethyl)-2-oxooxazolidin-3-yl)phenyl)phenyl)acrylate 

Relevant articles and documents

Synthesis and antibacterial activity evaluation of novel biaryloxazolidinone analogues containing a hydrazone moiety as promising antibacterial agents

A series of linezolid analogues containing a hydrazone moiety were designed, synthesized and evaluated for their antibacterial activity. Most compounds exhibited more potent antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens as compared with linezolid and radezolid. Compounds 9a, 9c, 9f, 9g, 10m and 10t were more potent against tested clinical isolates of MRSA, MSSA, VRE and LREF as compared to linezolid. Compound 9a exhibited comparable activity with linezolid against human MAO-A for safety evaluation and showed moderate metabolism in human liver microsome. The most promising compound 9a showed remarkable antibacterial activity against S.aureus, MRSA, MSSA, LREF and VRE pathogens with MIC value of 0.0675 mg/mL, respectively, which was 15- to 30-fold more potent than linezolid.

Oxazolidinone compound containing combined aromatic hydrazine and its preparation method

The invention relates to oxazolidinone compound containing combined aromatic hydrazine shown in general formula I, its optical isomer, pharmaceutical acceptable salt and/or solvent compound, and it preparation method, and the drug composition containing the compound, wherein the substituent groups R1, R2, R3, X and A rings have the meaning given in the specification. The invention further relatesto the compound, the substituent group, solvent compound or application of its prodrug using as antibacterial drug in treatment, and application of treating gram positive bacterial infection and mycobacterium tuberculosis infection especially.

NOVEL OXAZOLIDINONE DERIVATIVES, PROCESS FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to a novel oxazolidinone derivative, its prodrugs, hydrates, solvates, isomers, pharmaceutically permitted salts, and its preparation methods and pharmaceutical compositions containing the same. The oxazolidinone derivative and its pharmaceutically permitted salts according to the present invention have wide antimicrobial spectrum against resistant bacteria and low toxicity, and they show strong antibacterial effect against gram-positive and gram-negative pathogens. So, they can be used as good antibiotics.